Share Email Print

Journal of Biomedical Optics • Open Access

Preclinical evaluation of a novel cyanine dye for tumor imaging with in vivo photoacoustic imaging
Author(s): Takashi Temma; Satoru Onoe; Kengo Kanazaki; Masahiro Ono; Hideo Saji

Paper Abstract

Photoacoustic imaging (PA imaging or PAI) has shown great promise in the detection and monitoring of cancer. Although nanocarrier-based contrast agents have been studied for use in PAI, small molecule contrast agents are required due to their ease of preparation, cost-effectiveness, and low toxicity. Here, we evaluated the usefulness of a novel cyanine dye IC7-1-Bu as a PAI contrast agent without conjugated targeting moieties for in vivo tumor imaging in a mice model. Basic PA characteristics of IC7-1-Bu were compared with indocyanine green (ICG), a Food and Drug Administration approved dye, in an aqueous solution. We evaluated the tumor accumulation profile of IC7-1-Bu and ICG by in vivo fluorescence imaging. In vivo PAI was then performed with a photoacoustic tomography system 24 and 48 h after intravenous injection of IC7-1-Bu into tumor bearing mice. IC7-1-Bu showed about a 2.3-fold higher PA signal in aqueous solution compared with that of ICG. Unlike ICG, IC7-1-Bu showed high tumor fluorescence after intravenous injection. In vivo PAI provided a tumor to background PA signal ratio of approximately 2.5 after intravenous injection of IC7-1-Bu. These results indicate that IC7-1-Bu is a promising PAI contrast agent for cancer imaging without conjugation of targeting moieties.

Paper Details

Date Published: 8 September 2014
PDF: 3 pages
J. Biomed. Opt. 19(9) 090501 doi: 10.1117/1.JBO.19.9.090501
Published in: Journal of Biomedical Optics Volume 19, Issue 9
Show Author Affiliations
Takashi Temma, Kyoto Univ. (Japan)
Satoru Onoe, Kyoto Univ. (Japan)
Kengo Kanazaki, Kyoto Univ. (Japan)
Canon Inc. (Japan)
Masahiro Ono, Kyoto Univ. (Japan)
Hideo Saji, Kyoto Univ. (Japan)

© SPIE. Terms of Use
Back to Top